Quarter 2018 Financial Results

Quarter 2018 Financial Results

Israel - November 13, 2018 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company

focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for

the quarter ended September 30, 2018.

Quarter 2018 Financial Summary

are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.627 (NIS/$US) as at

of September 30, 2018, BiondVax had cash and cash equivalents of NIS 53.0 million ($14.6 million) as compared to NIS 37.1 million

as of June 30, 2018. Expenses are related to execution of planned ongoing operations including the launch of a pivotal, clinical

efficacy, Phase 3 trial of the Company's M-001 Universal Flu Vaccine candidate, and construction of a mid-size commercial

manufacturing facility.

note, during this third quarter a 6 million tranche was received by the Company as part of the previously announced 20

million co-financing agreement with the European Investment Bank (EIB). On October 21, 2018, after this third quarter reporting

period, an additional 8 million representing the third and final tranche of the EIB agreement was received by BiondVax,

and will be included in the Company's fourth quarter financial results.

(NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate,

called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus

strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides,

activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2

and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.

Please visit www.biondvax.com.

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to

certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results

to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,

but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing

of receipt of regulatory approval of the new manufacturing facility its products; ability to demonstrate the efficacy and safety

of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive

process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents

granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis, or

at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies;

the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the

risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on

Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available

on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. We undertake no obligation

to revise or update any forward-looking statement for any reason.

thousands, except share and per share data

OF COMPREHENSIVE INCOME

thousands, except share and per share data